非处方药市场－全球产业规模、份额、趋势、机会及预测（按产品、剂型、地区和竞争细分，2020-2030 年）

2024 年全球非处方药 (OTC) 市场价值为 102.5 亿美元，预计到 2030 年将达到 154.8 亿美元，预测期内的复合年增长率为 7.31%。 OTC 药物是一种方便且经济有效的选择，无需处方即可治疗头痛、过敏、感冒、消化问题和轻微皮肤刺激等常见健康状况。不断上涨的医疗成本和日益增长的自我照顾倾向是市场成长的主要推动因素。消费者正在寻求可获得的治疗替代方案，以减少对专业咨询的需求，这促使製药公司扩大其 OTC 产品组合，并投资于创新的给药方式和消费者意识计划。然而，市场扩张受到与不当使用相关的挑战的阻碍，包括过度使用的风险和自我药疗可能引起的併发症，尤其是在药剂师监督或监管执法有限的地区。

关键市场驱动因素

医疗保健产业的成长

主要市场挑战

滥用和自我用药的风险

主要市场趋势

利基OTC市场的成长

目录

第 1 章：产品概述

第二章：研究方法

第三章：执行摘要

第四章：COVID-19 对全球非处方药 (OTC) 市场的影响

第五章：全球非处方药（OTC）市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 副产品（咳嗽、感冒和流感、维生素、矿物质和补充剂 (VMS)、镇痛药、胃肠道产品、皮肤病学产品、其他）
  • 按剂型（片剂、胶囊、液体和溶液、乳膏/乳液/软膏、其他）
  • 按地区
  • 按公司分类（2024）
• 市场地图

第六章：北美非处方药（OTC）市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 美国
  • 墨西哥
  • 加拿大

第七章：欧洲非处方药（OTC）市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 法国
  • 德国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太非处方药（OTC）市场展望

• 市场规模和预测
• 市场占有率和预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 韩国
  • 日本
  • 澳洲

第九章：南美非处方药（OTC）市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第十章：中东和非洲非处方药（OTC）市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第 11 章：市场动态

• 驱动程式
• 挑战

第 12 章：市场趋势与发展

• 合併与收购（如有）
• 产品发布（如有）
• 最新动态

第十三章：干扰：衝突、流行病与贸易壁垒

第 14 章：全球非处方药 (OTC) 市场：SWOT 分析

第 15 章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 顾客的力量
• 替代产品的威胁

第 16 章：竞争格局

• Sanofi SA
• Pfizer Inc.
• GlaxoSmithKline plc
• Perrigo Company plc
• Reckitt Benckiser Group PLC
• Takeda Pharmaceutical Company Ltd
• Boehringer Ingelheim International GmbH
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.
• Glenmark Pharmaceuticals Ltd.

第 17 章：策略建议

第18章调查会社について・免责事项

The Global Over the Counter (OTC) Drugs Market was valued at USD 10.25 Billion in 2024 and is projected to reach USD 15.48 Billion by 2030, registering a CAGR of 7.31% during the forecast period. OTC drugs are a convenient and cost-effective option for managing common health conditions such as headaches, allergies, colds, digestive issues, and minor skin irritations without requiring a prescription. Increasing healthcare costs and a growing inclination toward self-care are major contributors to market growth. Consumers are seeking accessible treatment alternatives that reduce the need for professional consultations, prompting pharmaceutical companies to expand their OTC portfolios and invest in innovative delivery forms and consumer awareness initiatives. However, the market's expansion is tempered by challenges related to improper use, including risks of overuse and potential complications due to self-medication, particularly in regions with limited pharmacist oversight or regulatory enforcement.

Key Market Drivers

Growth in Healthcare Industry

The growing global healthcare industry significantly supports the expansion of the OTC drugs market. Generating over USD 4 trillion annually, the healthcare sector includes highly profitable domains such as pharmaceuticals and biotechnology, which contribute nearly USD 850 billion, and medical technology and diagnostics, accounting for more than USD 400 billion. As healthcare systems become more focused on patient-centered care and cost efficiency, consumers are increasingly turning to OTC medications to manage routine health issues independently. This shift reflects a broader movement toward preventative care, convenience, and greater consumer empowerment, which is driving demand for safe, effective, and readily available OTC treatment options.

Key Market Challenges

Risk of Misuse and Self-Medication

A major concern in the OTC drugs market is the potential for misuse and self-medication. The ease of access to OTC products, while beneficial for minor ailments, can result in unintended health risks when these products are used without adequate medical guidance. Improper dosing, extended use beyond recommended guidelines, or reliance on OTC drugs to manage symptoms of more serious conditions can lead to adverse outcomes. Misuse is particularly common with medications such as analgesics, antacids, and antihistamines, which consumers may not fully understand in terms of contraindications or possible drug interactions. This lack of oversight increases the risk of masking underlying illnesses or exacerbating health issues due to incorrect use.

Key Market Trends

Growth of Niche OTC Segments

The market is witnessing rising interest in niche OTC segments tailored to specific consumer needs and health conditions. As awareness of individual health concerns grows, consumers are seeking more targeted non-prescription solutions that go beyond general-purpose remedies. Categories such as sleep aids, digestive health supplements, women's health products, pediatric treatments, and plant-based options are gaining momentum. These offerings respond to a rising preference for self-managed wellness and preventive care. For instance, sleep aids typically rely on antihistamines like diphenhydramine and doxylamine to reduce wakefulness. Growing attention to conditions such as insomnia, digestive discomfort, and seasonal allergies has fueled demand for customized OTC solutions, encouraging companies to diversify their offerings and explore functional innovations aligned with consumer wellness trends.

Key Market Players

• Sanofi SA
• Pfizer Inc.
• GlaxoSmithKline plc
• Perrigo Company plc
• Reckitt Benckiser Group PLC
• Takeda Pharmaceutical Company Ltd
• Boehringer Ingelheim International GmbH
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.
• Glenmark Pharmaceuticals Ltd.

Report Scope

In this report, the Global Over the Counter (OTC) Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Over the Counter (OTC) Drugs Market, By Product:

• Cough
• Cold & Flu
• Vitamins, Mineral, & Supplements (VMS)
• Analgesics
• Gastrointestinal Products
• Dermatology Products
• Others

Over the Counter (OTC) Drugs Market, By Dosage Form:

• Tablets
• Capsules
• Liquids & Solutions
• Cream/Lotion/Ointments
• Others

Over the Counter (OTC) Drugs Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Over the Counter (OTC) Drugs Market.

Available Customizations

Global Over the Counter (OTC) Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Impact of COVID-19 on Global Over the Counter (OTC) Drugs Market

5. Global Over the Counter (OTC) Drugs Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Cough, Cold & Flu, Vitamins, Mineral, & Supplements (VMS), Analgesics, Gastrointestinal Products, Dermatology Products, Others)
  • 5.2.2. By Dosage Form (Tablets, Capsules, Liquids & Solutions, Cream/Lotion/Ointments, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Over the Counter (OTC) Drugs Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Dosage Form
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Over the Counter (OTC) Drugs Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Dosage Form
  • 6.3.2. Mexico Over the Counter (OTC) Drugs Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Dosage Form
  • 6.3.3. Canada Over the Counter (OTC) Drugs Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Dosage Form

7. Europe Over the Counter (OTC) Drugs Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Dosage Form
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Over the Counter (OTC) Drugs Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Dosage Form
  • 7.3.2. Germany Over the Counter (OTC) Drugs Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Dosage Form
  • 7.3.3. United Kingdom Over the Counter (OTC) Drugs Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Dosage Form
  • 7.3.4. Italy Over the Counter (OTC) Drugs Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Dosage Form
  • 7.3.5. Spain Over the Counter (OTC) Drugs Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Dosage Form

8. Asia Pacific Over the Counter (OTC) Drugs Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Dosage Form
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Over the Counter (OTC) Drugs Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Dosage Form
  • 8.3.2. India Over the Counter (OTC) Drugs Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Dosage Form
  • 8.3.3. South Korea Over the Counter (OTC) Drugs Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Dosage Form
  • 8.3.4. Japan Over the Counter (OTC) Drugs Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Dosage Form
  • 8.3.5. Australia Over the Counter (OTC) Drugs Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Dosage Form

9. South America Over the Counter (OTC) Drugs Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Dosage Form
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Over the Counter (OTC) Drugs Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Dosage Form
  • 9.3.2. Argentina Over the Counter (OTC) Drugs Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Dosage Form
  • 9.3.3. Colombia Over the Counter (OTC) Drugs Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Dosage Form

10. Middle East and Africa Over the Counter (OTC) Drugs Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Dosage Form
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Over the Counter (OTC) Drugs Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Dosage Form
  • 10.3.2. Saudi Arabia Over the Counter (OTC) Drugs Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Dosage Form
  • 10.3.3. UAE Over the Counter (OTC) Drugs Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Dosage Form

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Disruptions : Conflicts, Pandemics and Trade Barriers

14. Global Over the Counter (OTC) Drugs Market: SWOT Analysis

15. Porters Five Forces Analysis

• 15.1. Competition in the Industry
• 15.2. Potential of New Entrants
• 15.3. Power of Suppliers
• 15.4. Power of Customers
• 15.5. Threat of Substitute Products

16. Competitive Landscape

• 16.1. Sanofi SA
  • 16.1.1. Business Overview
  • 16.1.2. Company Snapshot
  • 16.1.3. Products & Services
  • 16.1.4. Financials (As Reported)
  • 16.1.5. Recent Developments
  • 16.1.6. Key Personnel Details
  • 16.1.7. SWOT Analysis
• 16.2. Pfizer Inc.
• 16.3. GlaxoSmithKline plc
• 16.4. Perrigo Company plc
• 16.5. Reckitt Benckiser Group PLC
• 16.6. Takeda Pharmaceutical Company Ltd
• 16.7. Boehringer Ingelheim International GmbH
• 16.8. Sun Pharmaceutical Industries Ltd.
• 16.9. Teva Pharmaceutical Industries Ltd.
• 16.10. Glenmark Pharmaceuticals Ltd.

17. Strategic Recommendations

18. About Us & Disclaimer